Robert Zerbib

3.0k citations

26 papers · 722 indexed · h-index 12

Impact in

Immunology top 5%
- Immune Cell Function and Interaction
- T-cell and B-cell Immunology
- Immunotherapy and Immune Responses
- Immune cells in cancer
Oncology top 5%
- CAR-T cell therapy research
- Cancer Immunotherapy and Biomarkers

Papers in ⓘ

Hematology 10
- Multiple Myeloma Research and Treatments 7
- Hematopoietic Stem Cell Transplantation 3
Immunology 12
- Immune Cell Function and Interaction 11

Co-authors: Pascale André (12 shared papers)Éric Vivier (2 shared papers)H Laborit (4 shared papers)Thorbald van Hall (1 shared paper)Amir Horowitz (1 shared paper)Émilie Narni-Mancinelli (1 shared paper)Dan Fu Ruan (1 shared paper)Sjoerd H. van der Burg (1 shared paper)
Journals: Journal of Clinical Oncology (4 papers)Blood (4 papers)Annals of Oncology (3 papers)Cancer Research (2 papers)Clinical Cancer Research (1 paper)
Partner nations: France United States Netherlands

In The Last Decade

Robert Zerbib

24 papers receiving 711 citations

Peers

Countries citing papers authored by Robert Zerbib

Since Specialization

Citations

This map shows the geographic impact of Robert Zerbib's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert Zerbib with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert Zerbib more than expected).

Fields of papers citing papers by Robert Zerbib

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert Zerbib. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert Zerbib. The network helps show where Robert Zerbib may publish in the future.

Co-authors

The 25 scholars most cited alongside Robert Zerbib, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Robert Zerbib Line = papers co-authored together Robert Zerbib links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 26 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Monalizumab: inhibiting the novel immune checkpoint NKG2A Journal for ImmunoTherapy of Cancer ·Thorbald van Hall, Pascale André, Amir Horowitz, Dan Fu Ruan, Linda Borst, Robert Zerbib, Émilie Narni-Mancinelli, Sjoerd H. van der Burg, Éric Vivier	2019	202
2	A Phase I Trial of the Anti-KIR Antibody IPH2101 and Lenalidomide in Patients with Relapsed/Refractory Multiple Myeloma Clinical Cancer Research ·Don M. Benson, Adam D. Cohen, Sundar Jagannath, Nikhil C. Munshi, Gary Spitzer, Craig C. Hofmeister, Yvonne A. Efebera, Pascale André, Robert Zerbib, Michael A. Caligiuri	2015	147
3	A phase 1 study of lirilumab (antibody against killer immunoglobulin-like receptor antibody KIR2D; IPH2102) in patients with solid tumors and hematologic malignancies Oncotarget ·Norbert Vey, Lionel Karlin, Sophie Sadot‐Lebouvier, Florence Broussais, Dominique Berton-Rigaud, Jérôme Rey, Aude Charbonnier, Delphine Marie, Pascale André, Carine Paturel, Robert Zerbib, Jaafar Bennouna, Gilles Salles, Anthony Gonçalvès	2018	110
4	Thalidomide versus dexamethasone for the treatment of relapsed and/or refractory multiple myeloma: results from OPTIMUM, a randomized trial Haematologica ·Martin Kropff, H Baylon, Jens Hillengaß, Tadeusz Robak, Roman Hájek, Peter Liebisch, Vesselina Goranova‐Marinova, C. Hulin, J Bladé, Tommaso Caravita, Hervé Avet‐Loiseau, Thomas Moehler, C. Pattou, Lela M. Lucy, Elisabeth Kueenburg, Axel Glasmacher, Robert Zerbib, T. Facon	2011	43
5	Anxiolytic activity of melatonin in mice: involvement of benzodiazepine receptors. PubMed ·G Pierrefiche, Robert Zerbib, H Laborit	1993	38
6	Combination of monalizumab and cetuximab in recurrent or metastatic head and neck cancer patients previously treated with platinum-based chemotherapy and PD-(L)1 inhibitors. Journal of Clinical Oncology ·Roger B. Cohen, Jessica R. Bauman, Sébastien Salas, A. Dimitrios Colevas, Caroline Even, Didier Cupissol, Marshall R. Posner, G. Lefebvre, Esma Saâda-Bouzid, Maureen Bernadach, Tanguy Y. Seiwert, Alexander T. Pearson, Franceline Calmels, Robert Zerbib, Pascale André, Federico Rotolo, Agnès Boyer-Chammard, Jérôme Fayette	2020	32
7	A multicenter prospective randomized study testing non-inferiority of thalidomide 100 mg/day as compared with 400 mg/day in patients with refractory/relapsed multiple myeloma: Results of the final analysis of the IFM 01–02 study Journal of Clinical Oncology ·Ibrahim Yakoub‐Agha, Chantal Doyen, Cyrille Hulin, Gérald Marit, Laurent Voillat, B. Grosbois, J-L Harousseau, Corinne Duguet, Robert Zerbib, Thierry Façon, J. Y. Mary	2006	28
8	Monalizumab in combination with cetuximab in patients (pts) with recurrent or metastatic (R/M) head and neck cancer (SCCHN) previously treated or not with PD-(L)1 inhibitors (IO): 1-year survival data Annals of Oncology ·Romain Cohen, G. Lefebvre, Marshall R. Posner, Jessica R. Bauman, Sébastien Salas, Caroline Even, Esma Saâda-Bouzid, Tanguy Y. Seiwert, Dimitrios Colevas, Franceline Calmels, Robert Zerbib, Pascale André, Agnès Boyer-Chammard, Jérôme Fayette	2019	16
9	A phase 1 dose-escalation study of IPH2102 (lirilumab, BMS-986015, LIRI), a fully human anti KIR monoclonal antibody (mAb) in patients (pts) with various hematologic (HEM) or solid malignancies (SOL). Journal of Clinical Oncology ·Norbert Vey, Anthony Gonçalvès, Lionel Karlin, Sophie Lebouvier-Sadot, Florence Broussais, Delphine Marie, Dominique Berton-Rigaud, Pascale André, Robert Zerbib, Renaud Buffet, Thomas Prébet, Aude Charbonnier, Jérôme Rey, Arnaud Pigneux, Jaafar Bennouna, Nicolas Boissel, Gilles Salles	2015	15
10	Results of a phase II study evaluating monalizumab in combination with cetuximab in previously treated recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) Annals of Oncology ·Jérôme Fayette, G. Lefebvre, Marshall R. Posner, Jessica R. Bauman, Sébastien Salas, Caroline Even, Esma Saâda-Bouzid, Tanguy Y. Seiwert, Dimitrios Colevas, Franceline Calmels, Robert Zerbib, A. Boyer Chammard, Roger B. Cohen	2018	15
11	Chronic stress and memory: Implication of the central cholinergic system Pharmacology Biochemistry and Behavior ·Robert Zerbib, H Laborit	1990	14
12	Preliminary results of STELLAR-001, a dose escalation phase I study of the anti-C5aR, IPH5401, in combination with durvalumab in advanced solid tumours Annals of Oncology ·Christophe Massard, Philippe A. Cassier, Johanna C. Bendell, Delphine Marie, Mathieu Bléry, Chris Morehouse, Maria Libera Ascierto, Robert Zerbib, Emmanuel Mitry, A. W. Tolcher	2019	14
13	483 Association of COVID-19 inflammation with activation of the C5a-C5aR1 axis SHILAP Revista de lepidopterología ·Olivier Demaria, Julien Carvelli, Nassima Chouaki Benmansour, Joanna Fares, Luciana Batista, Marie‐Laure Thibult, Ariane Morel, Sabrina Carpentier, Romain Remark, Agnès Représa, Frédéric Vely, Mikaël Ebbo, N. Schleinitz, Robert Zerbib, Yannis Morel, Éric Vivier	2020	11
14	Abstract CT158: Phase II study of monalizumab, a first-in-class NKG2A monoclonal antibody, in combination with cetuximab in previously treated recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Preliminary assessment of safety and efficacy Cancer Research ·Roger B. Cohen, Jérôme Fayette, Marshall R. Posner, G. Lefebvre, Jessica R. Bauman, Sébastien Salas, Caroline Even, Tanguy Y. Seiwert, Dimitrios Colevas, Antonio Jimeno, Esma Saâda, Barbara Burtness, Pascale André, Carine Paturel, Cécile Bonnafous, Anne-Marie Soulié, Anne Tirouvanziam-Martin, Robert Zerbib, Agnès Boyer-Chammard	2018	10
15	Repeated Dosing Of Anti-KIR (IPH2101) As Maintenance Therapy In Ederly Patients With Acute Myeloid Leukemia Blood ·Norbert Vey, Jean Bourhis, Christian Récher, Anne Etienne, Aude Charbonnier, Pascale André, Jérôme Rey, Franceline Calmels, Robert Zerbib, Renaud Buffet, Thomas Prébet	2013	6
16	Role of various second messengers in the memorization of a passive or active avoidance H Laborit, Robert Zerbib	1987	5
17	A Phase I Trial Of Anti-KIR Monoclonal Antibody IPH2101 and Lenalidomide For Multiple Myeloma Blood ·Don M. Benson, Adam D. Cohen, Craig C. Hofmeister, M Nikhil, Sundar Jagannath, Yvonne A. Efebera, Gary Spitzer, Robert Zerbib, Pascale André, Shawna Oxier, Michael A. Caligiuri	2013	3
18	Intergroup ALFA/GOELAMS randomized phase II trial of lirilumab anti-KIR monoclonal antibody (IPH2102/BMS986015) as maintenance treatment in elderly patients with acute myeloid leukemia (EFFIKIR trial). Journal of Clinical Oncology ·Norbert Vey, Hervé Dombret, Norbert Ifrah, Arnaud Pigneux, Claude Gardin, Marc Buyse, Pascale André, Anne Tirouvanziam-Martin, Robert Zerbib, Renaud Buffet, Marcel Rozencweig	2013	3
19	Predictive Factors of Survival After Thalidomide Therapy in Advanced Multiple Myeloma: Long-Term Follow-Up of a Prospective Multicenter Nonrandomized Phase II Study in 120 Patients Clinical Lymphoma Myeloma & Leukemia ·Olivier Decaux, Alain Renault, Véronique Sebille, Philippe Moreau, Michel Attal, Laurent Voillat, Brigitte Pegourié, Mourad Tiab, Thierry Façon, Robert Zerbib, B. Grosbois, Éric Bellissant	2012	2
20	Abstract 5666: Safety of the first-in-class anti-NKG2A monoclonal antibody monalizumab in combination with cetuximab: a phase Ib/II study in recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) Cancer Research ·Roger B. Cohen, Sébastien Salas, Caroline Even, Nuria Kotecki, Antonio Jimeno, Anne-Marie Soulié, Anne Tirouvanziam-Martin, Robert Zerbib, Pascale André, Agnès Boyer-Chammard, Jérôme Fayette	2017	2

About Robert Zerbib

Robert Zerbib is a scholar working on Hematology, Immunology, Oncology, Behavioral Neuroscience and Infectious Diseases, having authored 26 papers that have together received 722 indexed citations. Recurring topics across this work include Immune Cell Function and Interaction (11 papers), Cancer Immunotherapy and Biomarkers (7 papers), Multiple Myeloma Research and Treatments (7 papers), CAR-T cell therapy research (5 papers), Cancer Treatment and Pharmacology (4 papers), Hematopoietic Stem Cell Transplantation (3 papers), COVID-19 Clinical Research Studies (3 papers) and Protein Degradation and Inhibitors (2 papers). The work is most often cited by research in Immunology (481 citations), Oncology (480 citations), Hematology (137 citations), Otorhinolaryngology (25 citations) and Behavioral Neuroscience (18 citations). Robert Zerbib has collaborated with scholars based in France, United States and Netherlands. Frequent co-authors include Pascale André, Éric Vivier, H Laborit, Thorbald van Hall, Amir Horowitz, Émilie Narni-Mancinelli, Dan Fu Ruan, Sjoerd H. van der Burg, Don M. Benson and Sundar Jagannath. Their work appears in journals such as Journal of Clinical Oncology, Blood, Annals of Oncology, Cancer Research and Clinical Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact